Veraxa Biotech’s Public Debut Marred by 99.7% SPAC Investor Exodus

BROOKLYN, N.Y. – March 13, 2026 – German drug developer VERAXA Biotech AG is set to become a publicly traded company after shareholders of its SPAC partner, Voyager Acquisition Corporation, approved their business combination. But the celebration is likely muted, as a staggering 99.67% of Voyager’s investors have opted to cash out, leaving the newly combined entity with a tiny fraction of the capital it once hoped to raise.

The shareholder vote on March 12th was a formality that belied the dramatic financial reality of the deal. Holders of 25,217,315 Class A shares exercised their right to redeem, pulling their money from the SPAC’s trust account. As a result, what was once a pool of up to $253 million will shrink to just $885,556. This massive investor flight casts a long shadow over VERAXA’s public market debut and raises urgent questions about its ability to fund its ambitious research and development pipeline.

A Hollow Victory

The deal, which will see the combined company renamed Veraxa Biotech Holding AG and trade on Nasdaq under the symbol "VRXA" pending final approval, now stands as a stark example of the risks inherent in the SPAC market. Special purpose acquisition companies are formed to raise capital from the public with the sole purpose of merging with a private company, providing it a streamlined path to a public listing and a significant cash infusion. For Voyager and VERAXA, the mechanism has delivered the listing but failed catastrophically on the cash delivery.

The near-unanimous redemption reflects a deep skepticism among Voyager's investors about the valuation or prospects of the merged entity. This trend has become increasingly common in the post-boom SPAC landscape, where investors, burned by underperforming de-SPACs, are quick to redeem their shares rather than risk their capital on a new, unproven public company.

For VERAXA, the financial whiplash is severe. The original agreement, struck in April 2025, was predicated on the SPAC’s trust account providing sufficient capital to fund at least two years of operations and clinical development. The less than one million dollars remaining is a rounding error compared to the tens or hundreds of millions required annually to advance complex therapies through clinical trials. The company has achieved its goal of going public, but it arrives on Wall Street with its pockets virtually empty, a hollow victory that solves one problem—public access—while creating a much more immediate one: survival.

Innovation Meets Financial Reality

The financial predicament is especially poignant given the promise of VERAXA's science. Born from research at the prestigious European Molecular Biology Laboratory (EMBL), the company is working at the cutting edge of cancer therapy. It specializes in developing next-generation antibody-based therapeutics, a class of drugs that has revolutionized oncology.

VERAXA's proprietary Bi-Targeted Antibody Cytotoxicity (BiTAC) platform aims to create highly specific treatments for solid tumors by using a dual-marker approach, potentially increasing efficacy while reducing the toxic side effects common in cancer treatments. Its pipeline includes nine discovery and development programs, with its most advanced candidate, VX-A901, already in Phase 1 clinical trials for treating elderly patients with Acute Myeloid Leukemia (AML).

The market for these therapies is enormous and growing exponentially. The global T-cell engager market is projected to reach $112 billion by 2030, while the antibody-drug conjugate (ADC) market is forecast to hit $57 billion in the same timeframe. VERAXA’s innovative approach positions it to compete in this lucrative space, but innovation in biotechnology is inextricably linked to capital. Without substantial funding, promising molecules languish in labs, and clinical trials cannot proceed. The chasm between VERAXA's scientific potential and its post-SPAC financial reality could not be wider.

The Scramble for Capital Begins

With the SPAC trust all but gone, VERAXA's management faces an immediate and critical challenge: securing new funding. The company had already been pursuing a "crossover" financing round from private investors, a common step for companies nearing a public offering. The success of that round has now become a make-or-break event.

Beyond private financing, the company will likely need to accelerate plans for strategic partnerships and licensing deals. By partnering with a larger pharmaceutical company, VERAXA could secure non-dilutive funding in the form of upfront payments and future milestone fees in exchange for rights to some of its drug candidates. This would provide a vital cash lifeline but may force the company to give up a significant portion of the future upside of its most promising assets.

Further options include a Private Investment in Public Equity (PIPE) or a secondary public offering. However, raising money from public market investors immediately after a de-SPAC transaction with such a high redemption rate will be challenging. The company's valuation will be under intense scrutiny, and any new equity issued would likely cause significant dilution for the few remaining public shareholders and VERAXA’s original backers. Furthermore, the company must still satisfy Nasdaq’s initial listing requirements, which include minimum thresholds for shareholder equity and the market value of publicly held shares—metrics that are now under severe pressure due to the redemptions.

A Bellwether for the Biotech SPAC Market

The Voyager-VERAXA deal serves as a cautionary tale and a potential bellwether for the future of SPACs in the capital-intensive biotech sector. While the SPAC boom of the early 2020s offered a fast track to public markets, the current environment is far more discerning and unforgiving.

The 99.67% redemption rate is a clear signal that the blank-check promise of easy capital is over. For biotech companies, which require a long and expensive path through clinical trials before generating any revenue, this market shift is particularly perilous. A public listing is of little use without the fuel to power the R&D engine.

This outcome will likely force other private biotech firms to reconsider their own paths to the public market, perhaps favoring a more traditional IPO or remaining private for longer to secure more stable, long-term funding. For Veraxa Biotech Holding AG, the journey as a public company begins not with a celebratory ringing of the Nasdaq bell, but with a race against time to secure the capital needed to turn its scientific promise into life-saving medicine. Its future, and the fate of its innovative cancer therapies, now hangs in the balance.